US Edition
Published • loading... • Updated
Novartis Adds to Its Immunology Prospects With Another Deal for Monte Rosa’s Molecular Glue Drugs
Novartis will pay $120 million upfront to Monte Rosa for immune disease drug development, with potential total payments reaching $5.7 billion based on milestones and royalties.
- On September 15, 2025, Novartis and Boston-based Monte Rosa Therapeutics announced a new collaboration focused on molecular glue degrader drugs for immune-mediated diseases.
- Following Monte Rosa’s 2023 collaboration with Roche, the new agreement grants Novartis exclusive rights to develop a therapy directed at an unspecified target, along with the opportunity to acquire two additional preclinical immune disease drug candidates.
- Monte Rosa will handle discovery and early testing using its AI-driven QuEEN platform, while Novartis will lead clinical development of licensed programs and provide commercialization support.
- Novartis will pay $120 million upfront, with potential total payments up to $5.7 billion including milestones and royalties; CEO Markus Warmuth said this strengthens Monte Rosa's financial position to reach multiple Phase 2 readouts.
- The agreement expands Novartis's portfolio in protein degradation and highlights its dedication to advancing protein degrader therapies as a novel strategy for treating immune-related diseases with significant unmet needs.
Insights by Ground AI
11 Articles
11 Articles
Novartis Adds to Its Immunology Prospects With Another Deal for Monte Rosa’s Molecular Glue Drugs
Novartis is paying $120 million up front to secure rights to a Monte Rosa molecular glue degrader drug candidate as well as options for two others. The two companies began working together last year under an alliance focused on immune mediated-diseases.
Coverage Details
Total News Sources11
Leaning Left0Leaning Right0Center4Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
